ROCHE HOLDING LTD S/ADR by Roche Holding Ltd Analyst Price Targets - Benzinga

ROCHE HOLDING LTD S/ADR by Roche Holding Ltd

RHHBYOTCQX

Trade with Public

Trade with Public

$54.97

-0.25-0.46%

At close: Sep 4, 5:00 PM EST

$54.97

0.0050.01%

After Hours: Sep 4, 4:00 PM EST

Overview NewsPrice TargetsFinancials Sentiment Ownership Compare

ROCHE HOLDING LTD S/ADR by Roche Holding Ltd Analyst Price Targets

Wall Street analyst price targets and consensus rating for ROCHE HOLDING LTD S/ADR by Roche Holding Ltd (RHHBY).

Price Target Range — 1 Quarters

Analyst Consensus — 1 Analysts

1Hold

Consensus RatingMarket Perform# Analysts1Avg. Consensus PT$40Upside to Avg. PT-27.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 12, 2023	TD Cowen	Steve Scala	PT Cut	Market Perform	$45→$40

Analyst Ratings News

The Multiple Sclerosis Drug Race Just Got Hotter After Novartis’ Phase 3 Win

Novartis stock spikes 5% on positive Phase 3 REMODEL trial results for relapsing MS drug remibrutinib with no liver safety signals.

Vandana Singh

Immunic's Next-Gen Oral Multiple Sclerosis Drug Poised To Capture Share, Analyst Says

Stifel initiates coverage on Immunic (IMUX) with a Buy rating. Analysts see potential for VidoCa to disrupt the MS market via better safety.

Vandana Singh

Genmab Lymphoma Study Misses Key Target, Analyst Still Sees Upside

Genmab shared Phase 3 trial results for epcoritamab in lymphoma, missing overall survival but improving disease control, as analyst weighs approval risks and future trial data.

Vandana Singh

Analyst Upgrade Boosts Shattuck On Confidence In Next-Gen Inflammatory Bowel Disease Therapy

HC Wainwright upgrades Shattuck Labs on confidence in SL-325, a DR3 antibody aiming for stronger, durable IBD treatment amid TL1A concerns.

Vandana Singh

Cancer Focused Olema Pharmaceuticals Stock Soars 150% - Here's Why

Roche posts positive phase 3 results for giredestrant in early breast cancer, showing improved disease-free survival and a favorable safety profile.

Vandana Singh

Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity

William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therapy pipeline.

Vandana Singh